A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, S, Wrigley, J, East, C, Hern, A, Marshall, A, Dunn, J, Lorigan, P, Middleton, M, Corrie, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2008
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234061/
https://www.ncbi.nlm.nih.gov/pubmed/22275984
http://dx.doi.org/10.3332/ecancer.2008.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234061/
https://www.ncbi.nlm.nih.gov/pubmed/22275984
http://dx.doi.org/10.3332/ecancer.2008.108

Ejemplares similares